Opinion|Videos|May 19, 2026
Optimizing Administration of Zongertinib in HER2-Positive NSCLC
Author(s)Joshua K. Sabari, MD
Broad NGS guides metastatic NSCLC care, spotlights common HER2/ERBB2 variants, and explains when liquid biopsy falls short for targeted therapy.
Advertisement
Episodes in this series
Joshua K. Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with HER2 mutation–positive non–small cell lung cancer. He describes the standard weight-based dosing of the treatment as well as the adverse events to monitor early on to ensure optimal administration of zongertinib.
Advertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5